Kamada to Discontinue Phase 3 Trial of Inhaled AAT: Shares Fall

MT Newswires Live12-08

Kamada (KMDA) said Monday that it will discontinue the phase 3 trial of inhaled AAT for the treatment of Alpha-1 Antitrypsin Deficiency, or AATD, due to the "low likelihood of a successful efficacy outcome."

An independent data and safety monitoring board said the trial was unlikely to demonstrate a statistically significant benefit in its primary endpoint of lung function measured by FEV1, according to Kamada.

The company said it continues to supply its Glassia AAT-IV treatment in the US and other international markets.

Kamada also reiterated its 2025 revenue guidance of $178 million to $182 million and said it expects double-digit growth in 2026 revenue and profitability.

Shares of Kamada were down 8% in recent premarket activity.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589358437?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 20:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589358437","market":"fut","top_or_hot":-1,"title":"Kamada to Discontinue Phase 3 Trial of Inhaled AAT: Shares Fall","media":"MT Newswires Live","content":"<html><body><p> Kamada (KMDA) said Monday that it will discontinue the phase 3 trial of inhaled AAT for the treatment of Alpha-1 Antitrypsin Deficiency, or AATD, due to the \"low likelihood of a successful efficacy outcome.\"</p><p>An independent data and safety monitoring board said the trial was unlikely to demonstrate a statistically significant benefit in its primary endpoint of lung function measured by FEV1, according to Kamada.</p><p>The company said it continues to supply its Glassia AAT-IV treatment in the US and other international markets.</p><p>Kamada also reiterated its 2025 revenue guidance of $178 million to $182 million and said it expects double-digit growth in 2026 revenue and profitability.</p><p>Shares of Kamada were down 8% in recent premarket activity.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kamada to Discontinue Phase 3 Trial of Inhaled AAT: Shares Fall</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKamada to Discontinue Phase 3 Trial of Inhaled AAT: Shares Fall\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-08 20:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Kamada (KMDA) said Monday that it will discontinue the phase 3 trial of inhaled AAT for the treatment of Alpha-1 Antitrypsin Deficiency, or AATD, due to the \"low likelihood of a successful efficacy outcome.\"</p><p>An independent data and safety monitoring board said the trial was unlikely to demonstrate a statistically significant benefit in its primary endpoint of lung function measured by FEV1, according to Kamada.</p><p>The company said it continues to supply its Glassia AAT-IV treatment in the US and other international markets.</p><p>Kamada also reiterated its 2025 revenue guidance of $178 million to $182 million and said it expects double-digit growth in 2026 revenue and profitability.</p><p>Shares of Kamada were down 8% in recent premarket activity.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KMDA","symbol_name":"Kamada Ltd.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2589358437","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589358437","pubTimestamp":1765198200,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Kamada (KMDA) said Monday that it will discontinue the phase 3 trial of inhaled AAT for the treatment of Alpha-1 Antitrypsin Deficiency, or AATD, due to the \"low likelihood of a successful efficacy ou","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KMDA":"Kamada Ltd.","BK4160":"多样化房地产投资信托v","BK4139":"生物科技","AAT":"American Assets Trust Inc"},"translate_title":"Kamada将停止吸入AAT的3期试验：股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AAT":1.5,"KMDA":1.5},"content_text":"Kamada (KMDA) said Monday that it will discontinue the phase 3 trial of inhaled AAT for the treatment of Alpha-1 Antitrypsin Deficiency, or AATD, due to the \"low likelihood of a successful efficacy outcome.\"An independent data and safety monitoring board said the trial was unlikely to demonstrate a statistically significant benefit in its primary endpoint of lung function measured by FEV1, according to Kamada.The company said it continues to supply its Glassia AAT-IV treatment in the US and other international markets.Kamada also reiterated its 2025 revenue guidance of $178 million to $182 million and said it expects double-digit growth in 2026 revenue and profitability.Shares of Kamada were down 8% in recent premarket activity.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589358437","isCrawlerRequest":true}